One of the key reasons propelling the growth of the hydrocephalus shunts market is the rise in the incidence of brain and neurological disorders among people around the world.

Covid-19 Impact & Market Status

In 2020, most healthcare systems delayed or cancelled non-essential medical treatments as a result of mounting COVID-19 worry. The number of shunt procedures conducted during the pandemic unexpectedly dropped, especially the number of revision procedures. A number of medical device firms recently retracted or updated their 2020 sales and profitability forecasts. For instance, Medtronic forecasted a large decline in revenue across key markets in the second quarter of 2020 as a result of a decline in surgical operations. Globally, COVID-19 disrupted standard healthcare services. In order to protect patients, hospitals throughout the world saw a significant drop in elective surgical operations. Similarly, the post-pandemic expansion of the hydrocephalus shunts industry would be fuelled by the emergence of innovative technologies like the "eShunt system."

Ventriculo-peritoneal segment will hold majority of the market in the coming future

Based on type, the market for hydrocephalus shunts is split into four groups: ventriculo-peritoneal, ventriculo-pleural, ventriculo-atrial, and lumbo-peritonea. The ventriculo-peritoneal segment held the largest market share in 2021 and is expected to experience the greatest CAGR over the course of the forecast period.

The hydrocephalus valves segment is predicted to increase with the highest share

The hydrocephalus shunts market is segmented based on product type into hydrocephalus catheters, hydrocephalus catheter valves. The hydrocephalus valves are further divided into fixed pressure valves and pressure valves that may be adjusted. The segment is anticipated to rise as a result of technological developments in the devices designed to tackle biocompatibility, infection, and fouling problems. The market segment with the biggest share in 2021 was hydrocephalus valves. Additionally, it is projected that the hydrocephalus valves category would see the greatest CAGR throughout the projection period (2022-2029).

The pediatric segment is predicted to increase at the fastest CAGR in the coming future

On the basis of age group, the hydrocephalus shunts market is classified into pediatric and adults. The pediatric segment held a larger market share in 2021, and it is expected to register a higher CAGR during the forecast period (2022-2029).

The hospital segment is predicted to increase at the fastest CAGR in the coming future

The hydrocephalus shunts market is divided into paediatric and adult segments based on age groups. In 2021, the paediatric market category had a bigger market share, and it is anticipated that throughout the forecast period, it would have a higher CAGR (2022-2029).

North America market is expected to be a high growth rate in the near future

North America is predicted to make up a sizable percentage of the worldwide market due to the rise in patients with hydrocephalus and the growing attention on the treatment of neurological ailments. The usage of hydrocephalus shunts and the growth of this sector were prompted by the Hydrocephalus Association's estimate that 1 in every 1,000 newborns in the United States had hydrocephalus in 2019.

The US market is expanding as a result of the ageing population, an increase in neurological and brain disorders, and increased usage of advanced programmable valves. The enormous number of individuals affected by the illness is projected to fuel the market for these products. The US hydrocephalus shunts market will be driven by product releases, regulatory approvals, and greater focus by numerous companies on their expanding product portfolios in neurosurgery. For instance. In 2020, the M.blue Valve, the most recent iteration of hydrocephalus valve technology, was introduced by Aesculap Inc. in collaboration with Christoph Miethke GmbH & Co. KG. One valve houses both its distinctive gravity technology and a fixed differential pressure unit, enabling a straightforward, position-dependent solution.

Moreover, the expansion of the regional market is being greatly aided by rising healthcare costs and the presence of an established healthcare infrastructure.

The increased use of advanced programmable valves, cutting-edge shunts, and antisiphon devices by neurosurgeons to prevent syphon effects on cerebrospinal fluid and the rise in the number of elderly people are driving the market's expansion.

An excessive buildup of cerebrospinal fluid in the brain is known as hydrocephalus, which causes the intracranial pressure inside the skull to rise. Shunt systems can be implanted as a treatment for hydrocephalus. Cerebrospinal fluid is diverted from the ventricles of the brain, spinal cord, or subarachnoid regions to another body area where it is absorbed by a hydrocephalus shunt, which offers alternate fluid paths.

The market for hydrocephalus shunts is anticipated to expand significantly over the next years as a result of the widespread use of advanced programmable valves and the development of novel cerebrospinal fluid management techniques. Shunts, anti-siphon devices, and programmable pressure valves are among the latest medical technologies that neurosurgeons are more inclined to use. To lessen the effect of the syphon on cerebral fluid outflow, anti-siphon devices are utilize. As opposed to fixed pressure valves, programmable pressure valves are more widely used.

There are more incidences of brain damage due to an increase in accidents, self-harm, and falls. In addition to permanently affecting one's health, brain injuries can interfere with the brain's natural function. Most disabilities are caused by traumatic brain damage. According to CDC reports around 80,000 to 90,000 Americans have traumatic brain injury each year, leaving them incapacitated. The therapy for hemorrhagic stroke, severe damage, and acquired brain injury can all result in hydrocephalus.

When CSF flow is blocked or CSF pressure rises as a result of brain damage or injury, hydrocephalus occurs. The prevalence of hydrocephalus and the need for hydrocephalus shunts have both grown as a result of the rising number of accidents.

During the forecast period of 2022 to 2029, the hydrocephalus shunts market is anticipated to develop at a pace of 3.5% and is anticipated to reach USD 369.52 Million by 2029.

The dissemination of knowledge about hydrocephalus is a focus of several private and governmental organisations, which is anticipated to support the growth of the hydrocephalus shunt market throughout the forecast period. Campaigns to raise awareness about hydrocephalus are a priority for organisations like the "Hydrocephalus Association," which also provides suitable activities for those affected by the condition.

Furthermore, these organisations support hydrocephalus research to enhance diagnosis, treatment, and cure. The Hydrocephalus Association launched a new national campaign called "Roadmap to a Cure" in which the group committed to investing US$20 million by 2020 to speed up the support for hydrocephalus research and treatment. However, the high expense of shunt-related therapies and the requirement for revision operations restrict market expansion.

In line with this, this report provides a detailed analysis of several leading market vendors, which include Integra LifeSciences Corp, G. Surgiwear Lt, Fuji Systems Corp, Medtronic Plc, B. Braun Melsungen AG, HLL Lifecare Ltd, Spiegelberg GmbH & Co. KG, Kaneka Medix Corp., Johnson & Johnson, HPBio, G. Surgiwear Ltd (Chhabra Shunt System), Wellong Instruments Co., Ltd, Medicone, Spine Implantes, Sophysa SA. Furthermore, the Hydrocephalus Shunts market research study includes information on upcoming trends, opportunities, scope, and threats that will affect market growth. This report is being created to assist businesses in using and planning for any upcoming development prospects.

Latest Innovations in the Global Hydrocephalus Shunts Market: a Snapshot

• In August 2021, the National Institute of Neurological Disorders and Stroke (NINDS) awarded researchers a USD 14 million grant to investigate the efficacy of hydrocephalus therapy.
• In July 2019, the purchase of Arkis Biosciences Inc., a privately held provider of a variety of neurosurgical tools, including catheters, was announced by Integra LifeSciences. The purchase of Arkis Biosciences improved Integra's neurocritical care services and solidified Integra's position as the industry pioneer in cutting-edge catheter technology.

The market research analysis's objective is to offer reliable data on the world market for hydrocephalus shunts. The analysis decodes complex data, presents the history and current status of the sector, and forecasts market trends and size. All facets of the industry are investigated in the study, including market leaders, investors, clients, and new entrants.

Hydrocephalus Shunts Market Scope

Key Segments of the Global Hydrocephalus Shunts Market

Type Overview (USD Million)

• Ventriculo-Peritoneal
• Ventriculoatrial
• Ventriculo-Pleural
• Lumbo-Peritoneal

Product Type Overview (USD Million)

• Hydrocephalus Valves
  • Adjustable Pressure Valves
  • Fix Pressure Valves
• Hydrocephalus Catheters

Age Group Overview (USD Million)

• Pediatric
• Adult

End-User Overview (USD Million)

• Hospitals
• Ambulatory Surgical Centers

Regional Overview (USD Million)

North America

• U.S
• Canada

Europe

• Germany
• France
• UK
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• Rest of Asia Pacific

South America

• Mexico
• Brazil
• Rest of South America

The Middle East and South Africa